Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial - The Lancet HIV www.thelancet.com/journals/lan... 🧪
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-c...Long-acting bNAbs can sustain extended ART-free viral control in people treated during
early-stage HIV and represent a promising step towards achieving ART-free HIV remission.www.thelancet.com